THE GLOBAL IMMUNOTHERAPY DRUGS MARKET WAS VALUED AT USD 169.47 BILLION IN 2020 AND IS EXPECTED TO REACH USD 326.36 BILLION BY 2026, GROWING AT A CAGR OF 11.54%

The Global Immunotherapy Drugs Market Share, Size & Trends Analysis By Product (Monoclonal Antibodies, Immune System Modulators, Car T-Cell Therapies, and Others), By Application (Cancer, Auto Immune & Inflammatory Disease, and Others), and By Geography (North America, Europe, APAC, Latin America, and Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2021–2026.

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Download Free Sample

Most Exhaustive Report

210 Pages

35 Tables

75 Charts

5 Regions

18 Countries

21 Companies

3 Market Segment

IMMUNOTHERAPY DRUGS MARKET REPORT SCOPE

Report Attribute Details
MARKET SIZE (REVENUE) USD 326.36 BILLION (2026)
CAGR 11.54% (2021-2026)
BASE YEAR 2020
FORECAST YEAR 2021-2026
MARKET SEGMENTS By Product (Monoclonal Antibodies, Immune System Modulators, Car T-Cell Therapies, and Others), By Application (Cancer, Auto Immune & Inflammatory Disease, and Others)
GEOGRAPHIC ANALYSIS North America, Europe, APAC, Latin America, and Middle East & Africa
COUNTRIES COVERED US, Canada, Germany, UK, France, Italy, Spain, China, India, Japan, Australia, South Korea, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, and Turkey

GLOBAL IMMUNOTHERAPY DRUGS MARKET OVERVIEW

The global immunotherapy drugs market size was valued at USD 169.47 billion in 2020 and is expected to reach USD 326.36 billion by 2026, growing at a CAGR of 11.54%. The major factor responsible for growth in the immunotherapy drugs industry is an increase in demand for outsourcing the manufacturing of immunotherapy drugs by several biopharmaceuticals and biotechnological companies and resistance against conventional treatments. Major key players and other prominent vendors engaged in the immunotherapy drugs domain are constantly focussing on product launches, product approvals, R&D activities, and expanding their organic growth.

KEY HIGHLIGHTS

  • The emergence of various diseases in developing countries is propelling the usage of monoclonal antibodies, demanding the introduction of newer immunotherapies and creating opportunities for the market.
  • Cancer immunotherapy drugs revolutionized in cancer therapies that have begun to shift curve of cancer patients by increasing their lifespan.
  • The increasing immunotherapy drugs pipeline coupled with the emergence of the pandemic has scaled up the production of medicines.
  • By product, the adoptive cell therapy segment is expected to witness absolute growth of 1280% during the forecast period.
  • The recent trend of mergers and acquisitions is boosting the growth of the immunotherapy drugs industry. For instance, Bristol-Myers Squibb’s one of most recent and high-value transactions was the acquisition of Celgene in January 2018.

GLOBAL IMMUNOTHERAPY MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Product
  • Application
  • Geography

GLOBAL IMMUNOTHERAPY MARKET SEGMENTS

  • The monoclonal antibody segment accounted for the high share of 72.6% of the global immunotherapy drugs market in 2020. Significant advances in the field, notably, and the unprecedented results obtained using monoclonal antibodies that attach themselves to lymphocytes. This restores their functioning toward tumor cell and thus create a defense for the body against cancer.
  • The autoimmune diseases segment accounted for the highest market share in 2020. It is expected to post an incremental growth of USD 23.95 billion with 33% absolute growth during the forecast period. The segment's growth is attributed to the increase in the prevalence of immune-mediated inflammatory diseases (IMIDs), including autoimmune and auto-inflammatory diseases.
  • In 2020, the cancer segment accounted for the highest market share of 45.33%. Immunotherapies in oncology have been widely popularized by developing curative therapies, such as CAR T-cell. However, developing personalized therapies such as CAR T-cell to treat various types of cancers may pose significant challenges, such as educating medical personnel regarding the procedures and creating a convenient process for engineering T-cells of the patients and infusing them.

GEOGRAPHICAL ANALYSIS

  • North America: North America has the highest share among all the regions and is likely to witness an absolute growth of around 105% during the forecast period. The rise in the immunotherapy drugs industry is primarily attributable to the increasing incidence rates of various types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukemia, etc.
  • Europe: Europeans represent about one-tenth of the global population, yet one in four of all cancer diagnoses occur in this region. This region is likely to witness an absolute growth of around 84% during the forecast period. 
  • APAC: APAC is witnessing growing demand mainly due to a large and growing population. In APAC, various opportunities associated with the growth of the cancer immunotherapy drugs market are increasing, and government initiatives will further improve the healthcare sector.

VENDOR ANALYSIS

  • The major vendors such as F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.
  • Bristol Myers Squibb (BMS) is a biopharmaceutical company that is helping – outpatients in succeeding aliments by delivering innovative products. It has owned innovative drugs such as OPDIVO Immunotherapy Drugs for a wider range of diseases.
  • Market competitiveness is expected to increase during the forecast period as the vendors constantly focus on expanding their product portfolios.
  • Most of the leading key players are focusing on acquisitions, partnerships, diversifying their outsourcing services, and strengthening their distribution networks to increase their presence in the global market.
  • Established players are entering into various strategic alliances and co-marketing agreements to elevate competitiveness and penetration.


The global immunotherapy drugs market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

By Product

  • Monoclonal Antibodies
  • Immune System Modulators
  • Car T-Cell Therapies
  • Others

By Application

  • Cancer
  • Auto Immune & Inflammatory Disease
  • Others

By Geography

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
  • APAC
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Turkey

Frequently Asked Questions

The global immunotherapy drugs market was valued at USD 169.47 billion in 2020 and is projected to reach USD 326.36 billion by 2026.
The different product segmentation in the immunotherapy drugs market is monoclonal antibodies, immune system modulators, Car T-Cell therapies, and others.
North America is the region with the highest growth rate in the immunotherapy drugs industry.
The latest trends in the global immunotherapy drugs industry are next-generation immunotherapies, the impact of COVID-19 as a catalyst, and investment in research & development activities.
COVID-19 was a catalyst for the immunotherapy drugs industry as COVID-19, and non-COVID-19 related drugs and treatments continue to be developed and witnessed high demand during the period.
The key players in the global immunotherapy drugs industry are F. Hoffmann-La Roche, Bristol Myers Squibb Company, Merck & Co., Inc., GlaxoSmithKline, Novartis, AstraZeneca, and Janssen Pharmaceuticals Inc.
China and India are the major contributors in the Asia Pacific cancer immunotherapy market.
Download Free Sample
Read More

Select a license type that suits your business needs

Single User Licence
$3750.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4250.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5250.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Our Clients

Licence Types What are these?

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date